Estados Unidos - inglês - NLM (National Library of Medicine)

nostrum laboratories, inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 100 mg - carbamazepine extended-release capsules are indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types:      - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvements than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general ). carbamazepine extended-release capsules are indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline and nortriptyline. likewise, on theoretical grounds its use with monoamine oxidase inhibitors is not recommended. before administration of carbamazepine, mao inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits. coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. coadministration of carbamazepine with nefazodone is contraindicated. coadministration of carbamazepine extended-release capsules are contraindicated with delavirdine due to the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors. no evidence of abuse potential has been associated with carbamazepine, nor is there evidence of psychological or physical dependence in humans.

Estados Unidos - inglês - NLM (National Library of Medicine)

arkansas welding supply, inc. - oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065) - oxygen 992 ml in 1 l

Estados Unidos - inglês - NLM (National Library of Medicine)

arkansas welding & industrial supply - oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065) - oxygen 992 ml in 1 l

Estados Unidos - inglês - NLM (National Library of Medicine)

nostrum laboratories, inc. - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam 10 mg - piroxicam capsules are indicated: piroxicam capsules are contraindicated in the following patients: use of nsaids, including piroxicam capsules, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including piroxicam capsules, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of piroxicam capsules in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2% to 4% for major malformations, and 15% to 20% for pregnancy loss. in animal reproduction studies in rats and rabbits, there was no evidence of teratogenicity at exposures up to 5 and 10 times the maximum recommended human dose (mrhd), respectively. in rat studies with

Estados Unidos - inglês - NLM (National Library of Medicine)

nostrum laboratories, inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 100 mg - dermatitis herpetiformis: (d.h.) leprosy: all forms of leprosy except for cases of proven dapsone resistance.

Estados Unidos - inglês - NLM (National Library of Medicine)

nostrum laboratories, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Estados Unidos - inglês - NLM (National Library of Medicine)

arkansas welding supply, inc. - oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065) -

Estados Unidos - inglês - NLM (National Library of Medicine)

arkansas correctional industries - 12benzalkonium chloride 0.10% - do not use in the eyes stop use and ask a doctor if irritation and/or redness occurs or if symptoms persist for more than 72 hours. use for waterless cleansing of hands to decrease soil on the skin use for waterless cleansing of hands to decrease soil on the skin

Reino Unido - inglês - myHealthbox

bayer ag -

Estados Unidos - inglês - NLM (National Library of Medicine)

arkansas welding supply, inc. - nitrogen (unii: n762921k75) (nitrogen - unii:n762921k75) -